View Completed Webinar Join OCRFA and BFOR (BRCA Founder Outreach Study) for a free live webinar on May 22nd at 6PM EST to explore the roles of genetic testing in ovarian cancer, with Kelly Morgan, MS, CGC, Clinical Genetic Counselor at Memorial… Read on
(April 10, 2018) Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least a partial response to platinum based chemotherapy have a new, FDA approved option for maintenance therapy… Read on
(April 3, 2018) A study in the Journal of Clinical Oncology explored the effects of oncologists, rather than genetic counselors, testing ovarian cancer patients for BRCA mutations… Read on
(February 22, 2018) Researchers at Roswell Park Comprehensive Cancer Center, including Kunle Odunsi, MD, PhD, senior author of the study and current OCRFA Scientific Advisory Committee member, have discovered a mutation of an unidentified gene that… Read on
(February 14, 2018) Today the US Preventive Task Force updated their recommendation on ovarian cancer screening, reaffirming their 2012 position that screening average risk women for ovarian cancer is not effective in reducing mortality from the… Read on
(January 25, 2018) OCRFA has just awarded more than $5.3 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $80 million… Read on
Ovarian cancer is one of the leading causes of death for women. Approximately 15% of ovarian cancer harbors the inherited mutations in BRCA1 and BRCA2. The mutation carriers of BRCA1 and BRCA2 have up to 50% lifetime risk to develop ovarian cancer… Read on
Ovarian cancer incidence and mortality have remained essentially unchanged during the modern era of cancer treatment. Targeted therapy has emerged as a promising strategy in diverse cancer types, including ovarian cancers… Read on
Recent clinical trials showed that PARP inhibitors and platinum are effective in treating ovarian cancer patients with mutations BRCA1, BRCA2, and other genes encoding proteins involved in Homologous Recombination (HR), a form of DNA repair… Read on
Dr. Shih-Hsun Chen is currently a postdoctoral fellow at the Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, CA. Dr. Chen is working under the mentorship of Dr… Read on
(December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian cancer patients without BRCA mutations… Read on
(December 11, 2017) A study by the Ovarian Tumor Tissue Analysis Consortium, published in JAMA Oncology, looked at the association between cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) and overall survival with certain types of ovarian… Read on